The cytokeratin 17 expression in primary ovarian tumors has
diagnostic but not prognostic significance

J 2022

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

DUNDR, Pavel; Barbora BAZALOVA; Michaela BARTU; Tjalling BOSSE; Jana DROZENOVA et al.

Základní údaje

Originální název

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

Autoři

Vydání

Virchows Archiv, New York, Springer, 2022, 0945-6317

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30109 Pathology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.500

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/22:00127202

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Cytokeratin 17; Ovarian tumors; Gastrointestinal tract tumors; Differential diagnosis

Štítky

14110230, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 1. 2023 07:41, Mgr. Tereza Miškechová

Anotace

V originále

We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.

Návaznosti

90125, velká výzkumná infrastruktura

Název: BBMRI-CZ III

Citovat

DUNDR, Pavel; Barbora BAZALOVA; Michaela BARTU; Tjalling BOSSE; Jana DROZENOVA; Pavel FABIAN; Oluwole FADARE; Jitka HAUSNEROVÁ; Radek JAKSA; Jan LACO; Sigurd F. LAX; Radoslav MATEJ; W Glenn MCCLUGGAGE; Gabor MEHES; Romana MICHALKOVA; Kristyna NEMEJCOVA; Naveena SINGH; Naveena SINGH; Simona STOLNICU; Petr SKAPA; Marian SVAJDLER a Ivana STRUZINSKA. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. Virchows Archiv. New York: Springer, 2022, roč. 481, č. 2, s. 201-212. ISSN 0945-6317. Dostupné z: https://doi.org/10.1007/s00428-022-03338-z.

@article{2233282,
   author = {Dundr, Pavel and Bazalova, Barbora and Bartu, Michaela and Bosse, Tjalling and Drozenova, Jana and Fabian, Pavel and Fadare, Oluwole and Hausnerová, Jitka and Jaksa, Radek and Laco, Jan and Lax, Sigurd F. and Matej, Radoslav and McCluggage, W Glenn and Mehes, Gabor and Michalkova, Romana and Nemejcova, Kristyna and Singh, Naveena and Singh, Naveena and Stolnicu, Simona and Skapa, Petr and Svajdler, Marian and Struzinska, Ivana},
   article_location = {New York},
   article_number = {2},
   doi = {https://doi.org/10.1007/s00428-022-03338-z},
   keywords = {Cytokeratin 17; Ovarian tumors; Gastrointestinal tract tumors; Differential diagnosis},
   language = {eng},
   issn = {0945-6317},
   journal = {Virchows Archiv},
   title = {The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance},
   url = {https://link.springer.com/article/10.1007/s00428-022-03338-z},
   volume = {481},
   year = {2022}
}

TY  - JOUR
ID  - 2233282
AU  - Dundr, Pavel - Bazalova, Barbora - Bartu, Michaela - Bosse, Tjalling - Drozenova, Jana - Fabian, Pavel - Fadare, Oluwole - Hausnerová, Jitka - Jaksa, Radek - Laco, Jan - Lax, Sigurd F. - Matej, Radoslav - McCluggage, W Glenn - Mehes, Gabor - Michalkova, Romana - Nemejcova, Kristyna - Singh, Naveena - Singh, Naveena - Stolnicu, Simona - Skapa, Petr - Svajdler, Marian - Struzinska, Ivana
PY  - 2022
TI  - The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance
JF  - Virchows Archiv
VL  - 481
IS  - 2
SP  - 201-212
EP  - 201-212
PB  - Springer
SN  - 09456317
KW  - Cytokeratin 17
KW  - Ovarian tumors
KW  - Gastrointestinal tract tumors
KW  - Differential diagnosis
UR  - https://link.springer.com/article/10.1007/s00428-022-03338-z
N2  - We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.
ER  -

DUNDR, Pavel; Barbora BAZALOVA; Michaela BARTU; Tjalling BOSSE; Jana DROZENOVA; Pavel FABIAN; Oluwole FADARE; Jitka HAUSNEROVÁ; Radek JAKSA; Jan LACO; Sigurd F. LAX; Radoslav MATEJ; W Glenn MCCLUGGAGE; Gabor MEHES; Romana MICHALKOVA; Kristyna NEMEJCOVA; Naveena SINGH; Naveena SINGH; Simona STOLNICU; Petr SKAPA; Marian SVAJDLER a Ivana STRUZINSKA. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. \textit{Virchows Archiv}. New York: Springer, 2022, roč.~481, č.~2, s.~201-212. ISSN~0945-6317. Dostupné z: https://doi.org/10.1007/s00428-022-03338-z.

Přehled o publikaci